Analytical Data
-
基因名
HLA-E*01:03&B2M&Peptide(VMAPRTLVL) Monomer
- Application
-
别名
HLAE; sHLA-E; HLAE; MHC class I antigen E; MHC HLA-E alpha-1; MHC HLA-E alpha-2.1; MHC; QA1
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-8*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P13747 (G22-T302)&P61769
-
表达区间
P13747 (G22-T302)&P61769 (I21-M119)&VMAPRTLVL
-
氨基酸序列
P13747(HLA-E*01:03):GSHSLKYFHT SVSRPGRGEPRFISVGYVDDTQFVRFDNDAASPRMVPRAPWMEQEGSEYWDRETRSARDTAQIFRVNLRTLRGYYNQSEAGSHTLQWMHGCELGPDGRFLRGYEQFAYDGKDYLTLNEDLRSWTAVDTAAQISEQKSNDASEAEHQRAYLEDTCVEWLHKYLEKGKETLLHLEPPKTHVTHHPISDHEATLRCWALGFYPAEITLTWQQDGEGHTQDTELVETRPAGDGTFQKWAAVVVPSGEEQRYTCHVQHEGLPEPVTLRWKPASQPT
P61769 (B2M):IQRTPKIQVY SRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM
VMAPRTLVL -
分子量
52-65 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-E is a non-classical major histocompatibility complex (MHC) molecule that plays a crucial role in the immune response by presenting peptides to immune cells, particularly natural killer (NK) cells and CD8+ T cells. The HLA-E*01:03 variant, in conjunction with beta-2-microglobulin (B2M), forms a stable complex capable of binding specific peptides, such as VMAPRTLVL, derived from other MHC class I molecules. This interaction is critical for immune modulation and tolerance, making the study of HLA-E*01:03/B2M/Peptide monomers highly relevant for understanding immune evasion mechanisms employed by various pathogens and tumors. The reconstitution of this complex as a recombinant protein allows for detailed functional analyses, enabling researchers to investigate how HLA-E mediates NK cell inhibition and T cell activation. Additionally, this research could have clinical implications, particularly in the development of immunotherapies aimed at enhancing anti-tumor immunity or overriding immune tolerance in chronic infections. By exploring the structural and functional properties of HLA-E*01:03 in the context of its peptide binding capabilities, scientists aim to elucidate its role in immune regulation and identify potential therapeutic targets for enhancing immune responses against malignancies and infectious diseases.
